We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA has asked Ampio Pharma to conduct another clinical trial for its osteoarthritis med, Ampion, setting back its BLA and sending its stock down 79% on Wednesday and another 26% in premarket trading.